News

The Eurtac trial is the first prospective, randomized Phase III trial to investigate whether first line treatment with Tarceva is superior to chemotherapy in patients with epidermal growth

The proceeds of the offering will primarily be used to complete the company’s CE Mark application for the Neovasc Reducer product, a stent for the treatment of refractory

The Pfizer/ University College London (UCL) collaboration brings together the pioneering work of university researchers in the field of cell-based therapies and Pfizer’s expertise in the design and

According to Covidien, the Duet TRS reload offers preloaded tissue reinforcement on the Endo GIA universal range of laparoscopic staplers. The reinforcement material is a synthetic absorbable polymer

MediciNova and the Hercules Market of the Osaka Securities Exchange have reported final results from its Phase II clinical trial evaluating MN-221 at planned escalating doses of 240

The Perlegen intellectual property includes gene variants on chromosome 9p21 linked to increased risk of cardiovascular disease, especially in diabetic patients with poor glycemic control. The licensing agreement

According to ALR Technologies, the ALRT Health-E-Connect system is a communication tool for patients to provide ongoing diagnostic and adherence data to their physicians. Information provided by the

Maryland-based company Sanaria, with support from the PATH Malaria Vaccine Initiative, has initiated a Phase I clinical trial of its malaria vaccine candidate. Unlike other malaria vaccine candidates,

According to Quick-Med Technologies, Nimbus is a next-generation antimicrobial technology that is non-leaching, non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. Ladd Greeno,